Real-world utilization pattern of dydrogesterone in 7287 Indian women with obstetric and gynecological conditions: data from multicentric, retrospective study.


Journal

Revista brasileira de ginecologia e obstetricia : revista da Federacao Brasileira das Sociedades de Ginecologia e Obstetricia
ISSN: 1806-9339
Titre abrégé: Rev Bras Ginecol Obstet
Pays: Brazil
ID NLM: 9214757

Informations de publication

Date de publication:
2024
Historique:
received: 12 03 2023
accepted: 24 07 2023
medline: 20 5 2024
pubmed: 20 5 2024
entrez: 20 5 2024
Statut: epublish

Résumé

Despite the literature on dydrogesterone, studies on dydrogesterone utilization patterns are largely lacking in Indian patients. This was a multi-center, retrospective, observational, cross-sectional, and descriptive study across 817 centers in India. Data of patients who received dydrogesterone in past and provided consent for future use of their medical record for research purpose was were retrieved and analyzed. Data of 7287 subjects (aged 29.55±4.84 years) was analyzed. Threatened abortion was the most common indication for which the subjects received dydrogesterone (46.9%) followed by recurrent pregnancy loss. Polycystic ovary syndrome (PCOS), thyroid disorders and anemia were the most common comorbid conditions and prior pregnancy loss, advanced maternal age and obesity were the most common risk factors seen in subjects who received dydrogesterone. Total 27.5% of subjects received a loading dose of dydrogesterone, and majority (64%) received 40 mg as loading dose. 10 mg dose was used as maintenance or regular dose in 81.4% of the subjects. Twice daily (BID) was the most common dosing frequency (66.6%). The most common concomitant medications being taken by the subjects on dydrogesterone included folic acid (45.1%), iron supplements (30.3%) and calcium and vitamin D3 supplements (25.5%). Another progesterone preparation (oral, injection, vaginal, tubal) other than dydrogesterone was used concurrently in 7.8% of subjects. The study helped to identify the patient population that is benefitted by dydrogesterone and the preferred indications, risk factors, comorbid conditions and concomitant medication used in this patient population at real-life scenario.

Identifiants

pubmed: 38765536
doi: 10.61622/rbgo/2024AO18
pii: rbgo/2024AO18
pmc: PMC11075425
pii:
doi:

Types de publication

Journal Article Multicenter Study Observational Study

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© 2024. Federação Brasileira de Ginecologia e Obstetrícia. All rights reserved.

Déclaration de conflit d'intérêts

Conflicts to interest: none to declare.

Auteurs

Jaydeep Tank (J)

Ashwini Maternity and Surgical Hospital Mumbai India Ashwini Maternity and Surgical Hospital, Mumbai, India.

Sanjay Gupte (S)

Gupte Hospital and Centre for Research in Reproduction Pune - Obstetrics and Gynecology PuneMaharashtra India Gupte Hospital and Centre for Research in Reproduction, Pune - Obstetrics and Gynecology, Pune, Maharashtra, India.

Purna Chandra Mahapatra (PC)

Prachee Nursing Home Cuttack India Prachee Nursing Home, Cuttack, India.

Jayanthi Reddy (J)

J. J. Hospital Hyderabad India J. J. Hospital, Hyderabad, Hyderabad, India.

Pratima Mittal (P)

Vardhman Mahavir Medical College and Safdarjung Hospital New Delhi India Vardhman Mahavir Medical College and Safdarjung Hospital, New Delhi, India.

Ashish Kumar Mukhopadhyay (AK)

CSS College of Obstetrics Kolkata India CSS College of Obstetrics, Gynae. & Child health, Kolkata, India.

Lila Vyas (L)

Vyas Clinic JaipurRajasthan India Vyas Clinic, Jaipur, Rajasthan Jaipur, India.

Achla Batra (A)

Vardhman Mahavir Medical College and Safdarjung Hospital New Delhi India Vardhman Mahavir Medical College and Safdarjung Hospital, New Delhi, India.

Mahesh Gupta (M)

Pushpam Hospital Ahmedabad India Pushpam Hospital, Ahmedabad, India.

Sunita Tandulwadkar (S)

Ruby Hall Clinic IVF and Endoscopy Centre Pune India IVF and Endoscopy Centre, Ruby Hall Clinic, Pune, India.

Sunita Chandra (S)

Rajendra Nagar Hospital and IVF Center Lucknow India Rajendra Nagar Hospital and IVF Center, Lucknow, India.

Vidya Bhat (V)

Radhakrishna Multispecialty Hospital BangaloreKarnataka India Radhakrishna Multispecialty Hospital, Bangalore, Karnataka, India.

Kawita Bapat (K)

Bapat Hospital IndoreMadhya Pradesh India Bapat Hospital, Indore, Madhya Pradesh, India, Indore, India.

Parikshit Tank (P)

Ashwini Maternity and Surgical Hospital Mumbai India Ashwini Maternity and Surgical Hospital, Mumbai, India.

Ketan Kulkarni (K)

Emcure Pharmaceuticals PuneMaharashtra India Emcure Pharmaceuticals, Pune, Maharashtra, India.

Onkar Swami (O)

Emcure Pharmaceuticals PuneMaharashtra India Emcure Pharmaceuticals, Pune, Maharashtra, India.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH